Del Mar Pharmaceuticals - VAL-083 for Recurrent Glioblastoma Multiforme (GBM) brain cancer
Investigational clinical study of VAL-083 in adult patients with recurrent glioblastoma multiforme (GBM) previously treated with surgery and/or radiation and failed both Temodar® (temozolomide) and Avastin® (bevacizumab).
glioblastoma multiforme, GBM, glioma, refractory, recurrent, clinical trial, clinical study, clinical trials, clinical studies, brain cancer, investigational therapy, investigational therapies, clinical research, study, studies, therapy, therapies, bevaci
Is this your site? Certify your site and update informations
